These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 11106252

  • 1. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.
    Bianco C, Bianco R, Tortora G, Damiano V, Guerrieri P, Montemaggi P, Mendelsohn J, De Placido S, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2000 Nov; 6(11):4343-50. PubMed ID: 11106252
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
    Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, Fan Z, Mendelsohn J, Bianco AR, Tortora G.
    Clin Cancer Res; 1999 Apr; 5(4):909-16. PubMed ID: 10213228
    [Abstract] [Full Text] [Related]

  • 4. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).
    Bianco C, Tortora G, Bianco R, Caputo R, Veneziani BM, Caputo R, Damiano V, Troiani T, Fontanini G, Raben D, Pepe S, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2002 Oct; 8(10):3250-8. PubMed ID: 12374696
    [Abstract] [Full Text] [Related]

  • 5. Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis.
    Tortora G, Caputo R, Damiano V, Bianco R, Fontanini G, Cuccato S, De Placido S, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2001 Aug; 7(8):2537-44. PubMed ID: 11489837
    [Abstract] [Full Text] [Related]

  • 6. Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide.
    Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, Pepe S, Bianco AR, Agrawal S, Mendelsohn J, Tortora G.
    J Natl Cancer Inst; 1998 Jul 15; 90(14):1087-94. PubMed ID: 9672257
    [Abstract] [Full Text] [Related]

  • 7. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
    Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2003 Apr 15; 9(4):1566-72. PubMed ID: 12684433
    [Abstract] [Full Text] [Related]

  • 8. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth.
    Tortora G, Caputo R, Pomatico G, Pepe S, Bianco AR, Agrawal S, Mendelsohn J, Ciardiello F.
    Clin Cancer Res; 1999 Apr 15; 5(4):875-81. PubMed ID: 10213224
    [Abstract] [Full Text] [Related]

  • 9. Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production.
    Tortora G, Bianco R, Damiano V, Fontanini G, De Placido S, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2000 Jun 15; 6(6):2506-12. PubMed ID: 10873106
    [Abstract] [Full Text] [Related]

  • 10. Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.
    Tortora G, Caputo R, Damiano V, Caputo R, Troiani T, Veneziani BM, De Placido S, Bianco AR, Zangemeister-Wittke U, Ciardiello F.
    Clin Cancer Res; 2003 Feb 15; 9(2):866-71. PubMed ID: 12576461
    [Abstract] [Full Text] [Related]

  • 11. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
    Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G.
    Clin Cancer Res; 2000 May 15; 6(5):2053-63. PubMed ID: 10815932
    [Abstract] [Full Text] [Related]

  • 12. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A.
    Ciardiello F, Damiano V, Bianco R, Bianco C, Fontanini G, De Laurentiis M, De Placido S, Mendelsohn J, Bianco AR, Tortora G.
    J Natl Cancer Inst; 1996 Dec 04; 88(23):1770-6. PubMed ID: 8944008
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
    Barnes CJ, Ohshiro K, Rayala SK, El-Naggar AK, Kumar R.
    Clin Cancer Res; 2007 Jul 15; 13(14):4291-9. PubMed ID: 17634559
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225.
    Ye D, Mendelsohn J, Fan Z.
    Oncogene; 1999 Jan 21; 18(3):731-8. PubMed ID: 9989823
    [Abstract] [Full Text] [Related]

  • 19. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.
    Safavy A, Bonner JA, Waksal HW, Buchsbaum DJ, Gillespie GY, Khazaeli MB, Arani R, Chen DT, Carpenter M, Raisch KP.
    Bioconjug Chem; 2003 Jan 21; 14(2):302-10. PubMed ID: 12643740
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.